What is IVA stock price today?

IVA (Inventiva Sa) stock is trading at $5.50 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IVA stock going up or down today?

IVA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IVA stock now?

The decision to buy IVA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IVA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IVA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IVA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IVA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IVA's P/E ratio?

P/E ratio data for IVA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IVA's market cap?

IVA (Inventiva Sa) has a market capitalization of $1.14 billion, making it a small-cap stock.

What is IVA's price to book ratio?

IVA trades at a price-to-book (P/B) ratio of 2.10, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IVA pay dividends?

IVA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IVA's dividend yield?

IVA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IVA stock a good long-term investment?

IVA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IVA's revenue growth rate?

IVA has shown revenue growth of -0.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for IVA are available on our dashboard with complete income statement analysis.

What are the risks of investing in IVA?

Key risks for IVA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IVA compare to its competitors?

Compare IVA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IVA's performance and positioning.

What is IVA's stock price target for 2026?

Our AI model provides price targets for IVA based on fundamental analysis: Bull case $7.15 (+30%), Base case $6.32 (+15%), Bear case $4.95 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IVA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IVA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IVA's next earnings report?

IVA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IVA - Inventiva Sa

NYSE * Health Care * Biotechnology

$5.50

$-0.01 (-0.18%)

About Inventiva Sa

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

IVA Key Statistics

Market Cap

$1.14B

P/B Ratio

2.10

EPS

$-2.23

Revenue Growth

-0.8%

Employees

How IVA Compares to Peers

IVA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IVA(This stock)	$1.14B	N/A	-1%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Inventiva Sa Company Information

Headquarters: France
Website: inventivapharma.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 15, 2026 at 10:45 AM EDT

Ready to invest in IVA?

Commission-free trading available. Affiliate links.

Upcoming Events for IVA

Dashboard

Enter a ticker to analyze